Author
A. L. Welm
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2019-2022 · peak 4/yrCo-Author Collaboration Network
10 top collaborators · 41 mutual co-author links7 papers
Recent·Most cited
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity
M. L. Olson, E. R. Vander Mause, S. V. Radhakrishnan, J. D. Brody, A. P. Rapoport, A. L. Welm, D. Atanackovic, T. Luetkens
bioRxiv · Dec 5, 2021Bioengineering
PDXNet Portal: Patient-Derived Xenograft model, data, workflow, and tool discovery
S. Koc, M. W. Lloyd, J. Grover, S. Seepo, S. Lakshmi Subramanian, M. Ray, C. Frech, J. DiGiovanna, P. Webster, S. Neuhauser, A. Srivastava, X. Yi Woo, B. J. Sanderson, B. White, P. Lott, , J. H. Chuang
The paper introduces the PDXNet Portal, a centralized resource for PDX models and data, offering analysis workflows and facilitating cancer research collaboration.
bioRxiv · Oct 15, 2021Cancer Biology
Laterally transferred macrophage mitochondria acts as a signaling source promoting cancer cell proliferation
C. U. Kidwell, J. R. Casalini, S. Pradeep, S. D. Scherer, D. Greiner, J. S. Johnson, G. S. Olson, J. Rutter, A. L. Welm, T. A. Zangle, M. Roh-Johnson
The paper shows that dysfunctional macrophage mitochondria transferred to cancer cells promote proliferation via ROS-induced ERK signaling.
bioRxiv · Aug 10, 2021Cancer Biology
A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology
K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm
The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.
bioRxiv · Feb 28, 2021 · PreprintCancer Biology
ScRNA-seq reveals tumor microenvironment remodeling induced by local intervention-based immunotherapy
A. R. Hoover, K. Liu, C. I. Devette, J. R. Krawic, C. L. West, D. Medcalf, A. L. Welm, X.-H. Sun, W. H. Hildebrand, W. R. Chen
This study uses scRNA-seq to show that LIT induces proinflammatory cytokine signaling and immune cell activation in tumor microenvironments of MMTV-PyMT mice.
bioRxiv · Oct 2, 2020 · PreprintCell Biology
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
X. Y. Woo, J. Giordano, A. Srivastava, Z.-M. Zhao, M. W. Lloyd, R. de Bruijn, Y.-S. Suh, R. Patidar, L. Chen, S. Scherer, M. Bailey, C.-H. Yang, E. Cortes-Sanchez, Y. Xi, J. Wang, , B. E Welm
This study shows that copy number profiles are conserved in patient-derived xenografts (PDXs) through engraftment and passaging, indicating minimal impact from the mouse host on tumor evolution.
bioRxiv · Dec 3, 2019Cancer Biology